ANGO - CONFIRMED Breakout Above 52-Week High + MedTech FundamentAngioDynamics, Inc.BATS:ANGOshortermtrader📝 Post Text (Copy & Paste): 📍 ENTRY: $14.49 🛑 **STOP LOSS:** $11.70 (Risk: $2.79) 🎯 **TAKE PROFIT:** $20.78 (Reward: $6.29) 📊 R:R RATIO: ~1:2.2 🔍 TECHNICAL ANALYSIS (The Signal): Breakout confirmed! ANGO has successfully broken and closed above its 52-week high of $13.99**. I'm entering exactly at **$14.49 right at the moment of confirmation, avoiding any potential fakeout. Price has been building a solid base above the 200 SMA (approx. $11.48), which is acting as strong dynamic long-term support. The $11.70 stop loss** is strategically placed **below the 200 SMA and the key $12.44 support zone, giving the trade room to breathe without invalidating the bullish thesis. Target at **$20.78**: This approaches the highest analyst price target ($24) and represents a logical projection if the market continues to price in the growth of their Med Tech division. Additional confirmation: Volume on the breakout has been notably above average, validating the strength of the move. 📊 FUNDAMENTAL ANALYSIS (The Catalyst): AngioDynamics reported Q4 FY2026 earnings on July 14, and the numbers were exceptional: ✅ Revenue of $86.6M** beat expectations (+8% YoY). ✅ **Med Tech grew +16.7%** (7 consecutive quarters of double-digit growth). ✅ **NanoKnife surged +64.5%** with capital sales jumping +132.5%. ✅ **Gross margin expanded to 54.6%**. ✅ **Adjusted EBITDA of $13.2M (vs $7.6M in 2025). ✅ **Flawless balance sheet: $53.9M in cash and ZERO debt.** The key catalyst: Medicare coverage for NanoKnife went into effect on July 5, 2026, opening up a massive market for prostate and liver cancer treatments. Analysts at Canaccord Genuity raised their target to $20** and Lake Street to **$24, with a consensus "Strong Buy" rating. 🎯 TRADE STRATEGY: Entry at $14.49: Entering right at the moment of the confirmed breakout above the 52-week high. The confirmation is already priced in. SL at $11.70: Placed safely below the 200 SMA and structural support. If price loses this level, the long-term bullish thesis would be invalidated. TP at $20.78: Positioned near analyst target zones and the next psychological resistance level. ⚠️ RISK MANAGEMENT: The company is still posting GAAP losses (-$0.88 per share in FY2026) and the CEO transition could create short-term volatility. Additionally, NanoKnife capital sales can be lumpy quarter to quarter. This is exactly why a strict stop loss is non-negotiable on this trade. 💬 What are your thoughts? Is anyone else watching this breakout, or do you think we need to see a pullback before the next leg up? ⚠️ DISCLAIMER: This is NOT financial or investment advice. This post reflects my personal opinion and analysis based on publicly available information. Trading and investing involve substantial risk, including the potential loss of your entire capital. Past performance does not guarantee future results. Always do your own research (DYOR) and consult with a licensed financial advisor before making any trading decisions. I am not responsible for any losses incurred. #ANGO #Earnings #MedTech #Breakout #TradingSetup #TechnicalAnalysis #Stocks #NanoKnife